Waters (WAT) Stock Forecast & Price Target

Waters is supported by a powerful replacement cycle in liquid chromatography and mass spectrometry, with Alliance iS priced 15%–20% above prior models and about 20% of LC replacements shifting to the new platform, which should lift ASPs and margins over several years. The early-2026 merger with Becton Dickinson’s life science and diagnostics business roughly doubled the company, added exposure to diagnostics and discovery-related tools, and created meaningful synergy potential, including about $200 million of cost savings and 170–200 bps of operating-margin expansion by 2027. Its outlook is further strengthened by durable recurring revenue from consumables and service, around 7%–9% organic constant-currency growth expected in 2026, and embedded demand from regulated pharma, reshoring, and microbiology workflows.

Waters is facing a negative fundamental setup because the early 2026 merger with Becton Dickinson’s life science and diagnostics business adds structural complexity just as the acquired assets show share loss, weaker trends, and integration risk. The deal increases exposure to diagnostics and discovery-related tools, but it also brings about ~$4B of assumed debt, constraining capital allocation and raising the chance that management time and resources are diverted from the core analytical instruments franchise. Although the core business has benefited from post-COVID demand and U.S. reshoring, slower end-market recovery, competitive pressure, and potential multiple compression if growth disappoints create a fragile earnings profile.